Pause on the J&J COVID-19 vaccine will be taken forward in the US until there is not much information gathered on common blood clotting disorder is provided.
The decision was made by the federal advisory committee decided this Wednesday. The committee meeting will be held again within 7 to 10 days to gather more data that is wished to be accomplished.
In the past few days, six women and men were found with a similar combination of blood clots and fewer platelet counts between two weeks of receiving the johnson&johnson vaccine.
On the other hand, the eighth case with similar problems has been put to an ongoing investigation.
This Tuesday, the Health & Drug Authorities and other health care facilities advised putting a pause on the johnson & johnson vaccine as the after results of blood clots in a small number of people who were given the shots of the vaccine.
The rarest blood clots have been tested in seven people of the 7.2 million Americans who were given the shots of the J&J vaccine. The latest six cases were tried in women ages 18 to 48, and symptoms were in action within 6 to 13 days after receiving the vaccination. Among those people, one woman died, and the other three remain hospitalized.
The further information states that they did not see these side-effects with the Moderna or Pitzer-BioNtech vaccines, which are more widely available within the country’s boundaries in the United States.
The official Committee members stated in their statement that the procedure worked as it was expected to. It was a much faster-collecting evidence of a rare symptoms in a month of the vaccine being authorized.
